# Polycystic Ovary Syndrome Gets a New Name and Definition
The medical community has renamed polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS), reflecting a deeper understanding of the condition's complexity. The change acknowledges that PCOS affects far more than just the ovaries and involves multiple hormonal and metabolic systems throughout the body.
PCOS, now PMOS, is one of the most common endocrine disorders in women of reproductive age, affecting approximately 8 to 20 percent of women depending on diagnostic criteria used. The condition involves irregular menstrual cycles, elevated androgens (male hormones), and often insulin resistance or metabolic dysfunction.
The original name, polycystic ovary syndrome, proved misleading. Many women with the condition don't actually have cystic ovaries, yet they still receive the diagnosis. More fundamentally, the disorder extends well beyond reproductive organs. It involves insulin dysregulation, inflammation, adrenal dysfunction, and increased risk for type 2 diabetes and cardiovascular disease.
The renamed PMOS better captures the endocrine and metabolic nature of the disorder. This shift in terminology comes as researchers uncover the various pathways that trigger the syndrome. Some cases originate from insulin resistance. Others stem from inflammation or adrenal dysfunction. The condition likely has multiple distinct subtypes, each requiring different treatment approaches.
Common symptoms include irregular periods, excess facial or body hair, acne, hair loss, and difficulty conceiving. Diagnosis typically relies on finding two of three criteria: irregular ovulation, clinical or biochemical hyperandrogenism (excess androgens), and polycystic ovarian morphology on ultrasound.
Treatment remains individualized. Lifestyle modifications including weight loss, regular exercise, and dietary changes form the foundation.